2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2103

Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2699

Using ICD-10 Codes to Identify Patients with Systemic Sclerosis in the Electronic Health Record

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2612

Utility of Infiltration with Steroids in Dactilitis. Is the Infiltration Guided By Ecography Better THAN Conventional?

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2750

Utility of Methotrexate in Polymyalgia Rheumatica

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2763

Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2755

Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2101

UV-Induced Skin Inflammation Is Exacerbated in Lupus-Prone Ro60 Knockout Female Mice with Interferon Priming

Systemic Lupus Erythematosus – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2536

Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2400

Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2728

Validation of the Draft Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Indian Patients with ANCA Associated Vasculitis

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2471

Validation of the Functional Index for Hand Osteoarthritis (FIHOA) in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2736

Value of Histology for Diagnosis and Classification in ANCA Associated Vasculitis

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2724

Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2008

Vascular Adhesion Protein-1 (VAP-1) As Predictor of Radiographic Severity in Symptomatic Knee Osteoarthritis

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2075

Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].